This paper is in the following e-collection/theme issue:
RCTs - Protocols/Proposals (eHealth) (538) Obstetrics, Gynecology, and Reproductive Medicine (225) Pregnancy Information, Education and Lifestyle Interventions (300)Published on in Vol 11, No 10 (2022): October
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/37452, first published
.
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial
Authors of this article:
Pablo Garcia-Manau1 ; Manel Mendoza1 ; Erika Bonacina1 ; Raquel Martin-Alonso2, 3 ; Lourdes Martin4 ; Ana Palacios5, 6 ; Maria Luisa Sanchez7 ; Cristina Lesmes8 ; Ivan Hurtado9 ; Esther Perez10 ; Albert Tubau11 ; Patricia Ibañez12 ; Marina Alcoz13 ; Nuria Valiño14 ; Elena Moreno15 ; Carlota Borrero16 ; Esperanza Garcia17 ; Eva Lopez-Quesada18 ; Sonia Diaz19 ; Jose Roman Broullon20 ; Mireia Teixidor21 ; Carolina Chulilla22 ; Maria M Gil2, 3 ; Monica Lopez4 ; Amparo Candela-Hidalgo5, 6 ; Andrea Salinas-Amoros7 ; Anna Moreno8 ; Francesca Morra9 ; Oscar Vaquerizo10 ; Beatriz Soriano11 ; Marta Fabre12 ; Elena Gomez-Valencia13 ; Ana Cuiña14 ; Nicolas Alayon15 ; Jose Antonio Sainz16 ; Angels Vives17 ; Esther Esteve18 ; Vanesa Ocaña19 ; Miguel Ángel López20 ; Anna Maroto21 ; Elena Carreras1
There are currently no tweets available for this article within the specified range.